Posts

CMS Plans to Fast‑Track New Health Technologies and AI Tools for Medicare Beneficiaries

The Centers for Medicare & Medicaid Services (CMS) plans to fast‑track Medicare coverage and patient access to emerging health technologies, including artificial intelligence (AI) tools, as part of a broader effort to modernize U.S. healthcare delivery. CMS has established expedited coverage pathways such as the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway and the Transitional Coverage for Emerging Technologies (TCET) rule, which cut the gap between FDA approval and Medicare coverage from potentially more than a year to as little as two months and six months, respectively. CMS is expanding its "Health Tech Ecosystem" initiative, which includes partnerships with over 600 organizations to bring FHIR‑compatible apps, digital check‑in tools, and conversational AI (“AI agents”) to Medicare patients for chronic‑disease management, care navigation, and plan selection by 2026 milestones. The agency is also piloting AI‑driven prior‑authorization ...

RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea – 2026 update

Pfizer CFO to depart

U.S. Launches Section 301 Investigation into Germany Over Drug Pricing and Unfair R&D Burden in 2026

Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership

Shionogi Announces Supplemental Approval in Japan for Pediatric Dosage and Administration of XOCOVA to Treat COVID-19

cAMPfield Raises $180M to Bring PDE4 Inhibition to IBD

Portal Biotechnologies raises $9M for cell engineering tech that’s attracted Merck & Co., AbbVie

Novocure's bid to move electric fields therapy earlier in glioblastoma falls short

FDA panel strongly backs Moderna's mRNA flu vaccine for older adults, with final decision expected by early August 2026.

Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs

Friday Five: Verges neuro drug-to-data pivot

4 years after FDA snub, GSK partnership propels Spero’s Utebzi across approval finish line